Listed

SBC Medical Group Holdings Inc: Form 10-Q for the period ended Sep 30, 2025

Filed with the SEC on Nov 14, 2025 and accepted by EDGAR at Nov 14, 2025, 07:00 ET.

Share

Management's discussion and analysis

As filed, 47,567 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis summarize the significant factors affecting our operating results, financial condition, liquidity, and cash flows for the periods presented below, which should be read in conjunction with the unaudited consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”). The forward-looking statements contained herein are based on management’s judgment, assumptions made by management and information currently available to it. Actual results could differ materially from those discussed or implied in the forward-looking statements as a result of various factors, including those described elsewhere in this Quarterly Report and the Annual Report, particularly in “Part I, Item 1A. Risk Factors” of the Annual Report and the section entitled “Cautionary Note Regarding Forward-Looking Statements” herein.

Unless the context otherwise requires, any reference in this section of this Quarterly Report to the “Company,” “SBC,” “we,” “us” or “our” refers to Legacy SBC (defined below) and its consolidated subsidiaries and variable interest entity (“VIE”), prior to the consummation of the Business Combination and to SBC Medical Group Holdings Incorporated and its consolidated subsidiaries and VIE, following the Business Combination.

Overview

SBC Medical Group, Inc. (formerly known as SBC Medical Group Holdings Incorporated), a Delaware corporation and subsidiary of the Company (“Legacy SBC”) is a management company headquartered in Irvine, California and Tokyo, Japan, that provides management services to cosmetic treatment centers mainly in Japan.

On September 17, 2024, Legacy SBC consummated its going-public business combination with Pono Capital Two, Inc. (“Business Combination”). In connection with the closing of the Business Combination, Pono Capital Two, Inc. changed its name to SBC Medical Group Holdings Incorporated and the Company’s common stock began trading on Nasdaq under the ticker symbol “SBC”.

The Company and its subsidiaries are primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.

Our wholly owned subsidiary, SBC Medical Group Co., Ltd., a Japan corporation (“SBC Medical Sub”, or “SBC Japan”) is designated as a “medical service corporation” in Japan. In Japan, a medical service corporation is a legal entity that provides management service to “medical corporations”. The management services are conducted through franchisor-franchisee contracts and/or service contracts between SBC Medical Sub and the medical corporations that own all 258 of the treatment centers in Japan as of September 30, 2025. These clinics provide include but are not limited to breast augmentation, liposuction, rejuvenation treatments (including treatment of wrinkles, acne, scars, cellulite, excess fat, discoloration, and signs of aging), laser skin toning and spot removal, eyes double fold surgery, rhinoplasty, treatment of osmidrosis and hyperhidrosis, hair transplants, gynecological formation treatments, laser hair removal, face line surgeries, cosmetical dental procedures, tattoo removal, lasik eye surgery, lateral canthoplasty, brow lift procedures, androgenetic alopecia treatment, and cheek sagging prevention methods. In addition, similar management services are provided to four independently operated clinics.

The Company’s subsidiaries have entered into franchisor-franchisee contracts and service contracts with six medical corporations, consisting of Medical Corporation Shobikai, Medical Corporation Kowakai, Medical Corporation Nasukai, Medical Corporation Aikeikai, Medical Corporation Jukeikai and Medical Corporation Ritz Cosmetic Surgery. In addition, the Company has entered into service contracts since September 2023 with Medical Corporation Association Furinkai and Medical Corporation Association Junikai; and in July 2025 with Medical Corporation Misakikai and General Incorporated Association Miotokai, following the acquisition of MB Career Lounge Co., Ltd. (collectively with the six franchisee medical corporations, the “Medical Corporations and/or General Incorporated Associations” or “MCs”). All of the Medical Corporations and General Incorporated Associations are deemed to be related parties of the Company since relatives of the CEO of the Company are the members* of general meetings of members** of the Medical Corporations or General Incorporated Associations. The CEO of the Company was previously a member* of the six franchisee Medical Corporations until he ceased being a member* in July 2023. The Company, through SBC Medical Sub, owns equity interests*** of the six franchisee medical corporations. Although the Company, through SBC Medical Sub, has an equity interest*** to the rights to receive a distribution of residual assets in proportion to the amount of contribution in certain circumstances as provided in the Japanese Medical Care Act and in the articles of incorporation (except Medical Corporation Association Furinkai, Medical Corporation Association Junikai, Medical Corporation Misakikai and General Incorporated Association Miotokai), the Company or SBC Medical Sub does not have voting control over the corporate actions at general meetings of members** of the Medical Corporations or General Incorporated Associations per the requirements of the Japanese Medical Care Act.

* “Members (or shain) of general meeting of members (or shain)” means one of the organs of a Japanese Medical Corporation, and element of general meeting of members (as explained below) of the Medical Corporation. Each member (or shain) of general meeting of members (or shain) has one voting right.

** “General meeting of members (or shain)” means one of the organs of a Japanese Medical Corporation, and the highest decision-making body of the Medical Corporation, of which the main duties include the election and dismissal of directors (or riji) and corporate auditors (or kanji) of the Medical Corporation, and the approval of financial statements and statutory business reports of the Medical Corporation.

*** “Equity interest (or mochibun)” means the right to receive distribution of the residual assets of a Japanese Medical Corporation in proportion to the amount of contribution (Article 10.3.3.2 brackets of the Supplementary Provision of the Japanese Medical Care Act.). However, the procedures for an equity interest (or mochibun) holder to exercise and realize the right to receive distribution of the residual assets of the Medical Corporation is more complicated than that of a stock corporation due to the restrictions under the Medical Care Act.

Financial Overview

For the three months ended September 30, 2025 and 2024, we generated revenues of $43,353,235 and $53,084,883, respectively, we reported net income attributable to SBC Medical Group Holdings Incorporated of $12,824,636 and $2,832,894, respectively. For the nine months ended September 30, 2025 and 2024, we generated revenues of $134,040,783 and $160,995,005, respectively, we reported net income attributable to SBC Medical Group Holdings Incorporated of $36,785,322 and $40,075,054, respectively, and cash flows provided by (used in) operating activities of $(27,295,426) and $27,886,231, respectively. As of September 30, 2025, we had retained earnings of $226,248,329.

Our primary mission is to provide quality comprehensive management services to the MCs and expand our “Shonan Beauty Clinic” brand. We plan to achieve the mission by maintaining and strengthening our market position and brand in the cosmetic medical treatment management market in Japan, Vietnam and Singapore, and by growing our presence globally.

Further information regarding our business is provided in “Description of Business” of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025.

Results of Operations

Comparison of Results of Operations for the Three Months Ended September 30, 2025 and 2024

The following table summarizes our operating income as reflected in our unaudited consolidated statements of operations and comprehensive income for the three months ended September 30, 2025 and 2024, and presents information regarding amounts and percentage changes during those periods.

For the Three Months Ended September 30, 2025 Amount % of revenue 2024 Amount % of revenue Variance Amount%
Revenues, net (including net revenues provided to related parties) $43,353,235 100.00% $53,084,883 100.00% $(9,731,648) (18.33)%
Cost of revenues (including cost of revenues from related parties) 12,741,748 29.39% 9,845,793 18.55% 2,895,955 29.41%
Gross profit 30,611,487 70.61% 43,239,090 81.45% (12,627,603) (29.20)%
Operating expenses (including selling, general and administrative expenses from related parties) 14,730,247 33.98% 29,404,487 55.39% (14,674,240) (49.90)%
Income from operations 15,881,240 36.63% 13,834,603 26.06% 2,046,637 14.79%
Other income (loss) (including other income from related party) 2,625,624 6.06% (726,752) (1.37)% 3,352,376 (461.28)%
Income before income taxes 18,506,864 42.69% 13,107,851 24.69% 5,399,013 41.19%
Income tax expense 5,673,538 13.09% 10,273,384 19.34% (4,599,846) (44.77)%
Net income 12,833,326 29.60% 2,834,467 5.34% 9,998,859 352.76%
Less: net income attributable to non-controlling interests 8,690 0.02% 1,573 0.00% 7,117 452.45%
Net income attributable to SBC Medical Group Holdings Incorporated $12,824,636 29.58% $2,832,894 5.34% $9,991,742 352.70%

2

Revenues, Net

Revenues, net generated from different revenue streams consist of the following:

For the Three Months Ended September 30, 2025 2024 Variance Amount%
Franchising revenue $9,929,387 $15,688,528 $(5,759,141) (36.71)%
Procurement revenue 13,406,905 17,571,299 (4,164,394) (23.70)%
Management services revenue 9,462,183 12,110,764 (2,648,581) (21.87)%
Rental services revenue 6,219,645 4,124,774 2,094,871 50.79%
Others 4,335,115 3,589,518 745,597 20.77%
Total $43,353,235 $53,084,883 $(9,731,648) (18.33)%

Revenues, net, decreased by 18.33% from $53,084,883 for the three months ended September 30, 2024 to $43,353,235 for the three months ended September 30, 2025.

Japanese Yen (“JPY”) against the U.S. dollar appreciated during the three months ended September 30, 2025, compared to the three months ended September 30, 2024. The average rate against the dollar was 147.4096 yen for the three months ended September 30, 2025 compared to 148.9730 yen for the same period in 2024. For the three months ended September 30, 2025 and 2024, we generated net revenues of $43,353,235 (JPY6,391 million) and $53,084,883 (JPY7,908 million), respectively, we reported net income of $12,833,326 (JPY1,896 million) and $2,834,467 (JPY379 million), respectively. Overall, the favorable impacts of the period-to-period foreign exchange rate changes on net revenues and net income were $454,958 and $107,787, respectively, for the three months ended September 30, 2025.

The main reasons for the variance of $9,731,648 in revenues, net per revenue stream are as follows:

Franchising Revenue

Franchising revenue for the three months ended September 30, 2025, decreased to $9,929,387 by $5,759,141, or 36.71%, from $15,688,528 for the same period in 2024. This decrease was mainly due to the revision of the fee structure for determining service fees for each clinic of MCs based on the size, scale and performance of each clinic effective as of April 1, 2025, partially offset by the appreciation of JPY.

Procurement Revenue

The procurement revenue for the three months ended September 30, 2025 decreased to $13,406,905 by $4,164,394, or 23.70%, from $17,571,299 for the same period in 2024. This decrease was mainly due to a reduction in orders from MCs for the new types of medical materials, partially offset by the appreciation of JPY.

Management Services Revenue

The management services revenue for the three months ended September 30, 2025 decreased to $9,462,183 by $2,648,581, or 21.87%, from $12,110,764 for the same period in 2024. This decrease was mainly due to (i) the discontinuation of clinic operation staff supporting services that had been provided by Shobikai Sub to MCs since the third quarter of 2024, because the Company completed the merger of Shobikai Sub with and into Lange Sub and the related business license, held by Shobikai Sub, became invalid upon the merger in January 2025, (ii) the decrease in the revenue in connection with customer rewards program offered to customers of the franchisee clinics and (iii) the revision of the fee structure for determining service fees for each clinic of MCs based on the size, scale and performance of each clinic effective as of April 1, 2025, partially offset by revenues from MB Career Lounge Co., Ltd., which was acquired in July 2025 and by the appreciation of JPY.

Rental Services Revenue

The rental services revenue for the three months ended September 30, 2025 increased to $6,219,645 by $2,094,871, or 50.79%, from $4,124,774 for the same period in 2024. This increase was mainly due to the opening of new clinics resulting in the increased demand for medical equipment from new clinics and replacing laser hair removal equipment from existing clinics as well as the appreciation of JPY.

Others

The other revenues for the three months ended September 30, 2025 increased to $4,335,115 by $745,597, or 20.77%, from $3,589,518 for the same period in 2024. This increase was mainly due to revenues from Aesthetic Healthcare Holdings Pte. Ltd. and its subsidiaries, which were acquired in November 2024, offset by the disposal of its subsidiaries, Kijimadairakanko Inc. and Skynet Academy Co., Ltd. in December 2024.

Cost of Revenues

Cost of revenues for the three months ended September 30, 2025 was $12,741,748 compared to $9,845,793 for the same period in 2024. The increase was mainly due to higher purchase costs resulting from replacing laser hair removal equipment from MCs. The increase was partially offset by the discontinuation of clinic operation supporting services provided by Shobikai Sub to MCs since the third quarter of 2024, and the Company then terminated the employment of the related staff.

Gross Profit

Gross profit for the three months ended September 30, 2025 was $30,611,487 compared to $43,239,090 for the same period in 2024. The decrease in gross profit by $12,627,603 or 29.20% was mainly due to the decrease in franchising revenue, procurement revenue and management services revenue with relatively high gross margin as a result of the factors described above.

Operating Expenses

Operating expenses for the three months ended September 30, 2025 and 2024 were as follows:

For the Three Months Ended September 30, 2025 2024 Variance Amount%
Salaries and welfare $6,598,148 $6,842,278 $(244,130) (3.57)%
Depreciation and amortization expense 710,420 684,926 25,494 3.72%
Consulting and professional service fees 4,413,204 5,070,231 (657,027) (12.96)%
Advertising expense 300,675 621,759 (321,084) (51.64)%
Taxes and dues 70,772 151,609 (80,837) (53.32)%
Recruiting expense 158,019 201,987 (43,968) (21.77)%
Lease expense 607,885 602,787 5,098 0.85%
Office, utility and other expenses 1,871,124 2,421,455 (550,331) (22.73)%
Stock-based compensation — 12,807,455 (12,807,455) (100.00)%
Total $14,730,247 $29,404,487 $(14,674,240) (49.90)%

The operating expenses decreased to $14,730,247 for the three months ended September 30, 2025 by $14,674,240, or 49.90%, from $29,404,487 for the same period in 2024. The decrease was mainly due to the decrease in stock-based compensation, consulting and professional service fees, and office, utility and other expenses.

Stock-based compensation was recognized as an expense for the three months ended September 30, 2024 related to warrants issued to a service provider that supported SBC’s listing process. No such expense was recognized for the three months ended September 30, 2025.

Consulting and professional service fees decreased by $657,027, or 12.96%, to $4,413,204 for the three months ended September 30, 2025 from $5,070,231 for the same period in 2024, mainly due to the decrease in legal, tax, and market research expenses associated with the Company’s listing.

Other Income (Expenses)

Other income (expenses) for the three months ended September 30, 2025 and 2024, were as follows:

For the Three Months Ended September 30, 2025 2024 Variance Amount%
Interest income $120,384 $7,950 $112,434 1,414.26%
Interest expense (48,635) (5,466) (43,169) 789.77%
Other income 2,526,035 65,922 2,460,113 3,731.85%
Other expenses (6,564) (795,158) 788,594 (99.17)%
Change in fair value of cryptocurrencies 34,404 — 34,404 100.00%
Total $2,625,624 $(726,752) $3,352,376 (461.28)%

4

In particular, the other income was $2,526,035 for the three months ended September 30, 2025, as compared to $65,922 for the three months ended September 30, 2024, mainly due to the increase in an unrealized gain recognized on investment in a public entity with a readily determinable fair value - related party. The other expense was $6,564 for the three months ended September 30, 2025, as compared to $795,158 for the three months ended September 30, 2024, mainly due to a reduction of the foreign exchange losses recognized during the three months ended September 30, 2025. Change in fair value of cryptocurrencies was $34,404 for the three months ended September 30, 2025, as compared to nil for the three months ended September 30, 2024, reflecting from the fair value change of the cryptocurrencies purchased in April 2025 during the current period.

Income Tax Expense

Income tax expense for the three months ended September 30, 2025 was $5,673,538 compared to $10,273,384 for the same period in 2024. The decrease in income tax expense by $4,599,846 or 44.77% was mainly due to the prior-year recognition of $12,807,455 of non-deductible stock-based compensation recognized for the three months ended September 30, 2024, while no such expense was recorded in the three months ended September 30, 2025.

The effective tax rate was 30.66% and 78.38% for the three months ended September 30, 2025 and 2024, respectively. The decrease of 47.72 percentage points was mainly due to the prior-year recognition of $12,807,455 of non-deductible stock-based compensation recognized for the three months ended September 30, 2024, while no such expense was recorded in the three months ended September 30, 2025.

Net Income

As a result of the foregoing, we reported a net income of $12,833,326 for the three months ended September 30, 2025, representing an increase of $9,998,859 or 352.76% from $2,834,467 for the three months ended September 30, 2024.

Net Income Attributable to Non-controlling Interests

Net income attributable to non-controlling interests was $8,690 for the three months ended September 30, 2025, as compared to $1,573 for the three months ended September 30, 2024.

Comparison of Results of Operations for the Nine Months Ended September 30, 2025 and 2024

The following table summarizes our operating income as reflected in our unaudited consolidated statements of operations and comprehensive income for the nine months ended September 30, 2025 and 2024, and presents information regarding amounts and percentage changes during those periods.

For the Nine Months Ended September 30, 2025 Amount % of revenue 2024 Amount % of revenue Variance Amount%
Revenues, net (including net revenues provided to related parties) $134,040,783 100.00% $160,995,005 100.00% $(26,954,222) (16.74)%
Cost of revenues (including cost of revenues from related parties) 35,685,635 26.62% 38,816,865 24.11% (3,131,230) (8.07)%
Gross profit 98,355,148 73.38% 122,178,140 75.89% (23,822,992) (19.50)%
Operating expenses (including selling, general and administrative expenses from related parties) 43,717,642 32.62% 56,592,092 35.15% (12,874,450) (22.75)%
Income from operations 54,637,506 40.76% 65,586,048 40.74% (10,948,542) (16.69)%
Other income (including other income from related party) 8,861,126 6.61% 1,810,438 1.12% 7,050,688 389.45%
Income before income taxes 63,498,632 47.37% 67,396,486 41.86% (3,897,854) (5.78)%
Income tax expense 26,733,504 19.94% 27,254,478 16.92% (520,974) (1.91)%
Net income 36,765,128 27.43% 40,142,008 24.94% (3,376,880) (8.41)%
Less: net income (loss) attributable to non-controlling interests (20,194) (0.02)% 66,954 0.04% (87,148) (130.16)%
Net income attributable to SBC Medical Group Holdings Incorporated $36,785,322 27.44% $40,075,054 24.89% $(3,289,732) (8.21)%

5

Revenues, Net

Revenues, net generated from different revenue streams consist of the following:

For the Nine Months Ended September 30, 2025 2024 Variance Amount%
Franchising revenue $35,656,250 $45,425,052 $(9,768,802) (21.51)%
Procurement revenue 43,496,207 44,303,891 (807,684) (1.82)%
Management services revenue 23,328,864 44,471,031 (21,142,167) (47.54)%
Rental services revenue 18,711,335 11,195,888 7,515,447 67.13%
Others 12,848,127 15,599,143 (2,751,016) (17.64)%
Total $134,040,783 $160,995,005 $(26,954,222) (16.74)%

Revenues, net, decreased by 16.74% from $160,995,005 for the nine months ended September 30, 2024 to $134,040,783 for the nine months ended September 30, 2025.

Japanese Yen (“JPY”) against the U.S. dollar appreciated during the nine months ended September 30, 2025, compared to the nine months September 30, 2024. The average rate against the dollar was 148.1284 yen for the nine months ended September 30, 2025 compared to 151.1271 yen for the same period in 2024. For the nine months ended September 30, 2025 and 2024, we generated net revenues of $134,040,783 (JPY19,855 million) and $160,995,005 (JPY24,331 million), respectively, we reported net income of $36,765,128 (JPY5,458 million) and $40,142,008 (JPY6,067 million), respectively. Overall, the favorable impacts of the period-to-period foreign exchange rate changes on net revenues and net income were $2,659,670 and $651,055, respectively, for the nine months ended September 30, 2025.

The main reasons for the variance of $26,954,222 in revenues, net per revenue stream are as follows:

Franchising Revenue

Franchising revenue for the nine months ended September 30, 2025 decreased to $35,656,250 by $9,768,802, or 21.51%, from $45,425,052 for the same period in 2024. This decrease was mainly due to the revision of the fee structure for determining service fees for each clinic of MCs based on the size, scale and performance of each clinic effective as of April 1, 2025, partially offset by the appreciation of JPY.

Procurement Revenue

The procurement revenue for the nine months ended September 30, 2025 decreased to $43,496,207 by $807,684, or 1.82%, from $44,303,891 for the same period in 2024. This decrease was mainly due to the decrease in the orders from MCs for the medical materials which reflected a temporary increase in procurement activities associated with the opening of multiple new clinics in the same period of the prior year.

Management Services Revenue

The management services revenue for the nine months ended September 30, 2025 decreased to $23,328,864 by $21,142,167, or 47.54%, from $44,471,031 for the same period in 2024. This decrease was mainly due to (i) the discontinuation of clinic operation staff supporting services that had been provided by Shobikai Sub to MCs since the third quarter of 2024, because the Company completed the merger of Shobikai Sub with and into Lange Sub and the related business license that was held by Shobikai Sub became invalid upon the completion of the merger in January 2025, (ii) the decrease in the revenue in connection with customer rewards program offered to customers of the franchisee clinics and (iii) the revision of the fee structure for determining service fees for each clinic of MCs based on the size, scale and performance of each clinic effective as of April 1, 2025, partially offset by revenues from MB Career Lounge Co., Ltd., which was acquired in July 2025 and by the appreciation of JPY.

Rental Services Revenue

The rental services revenue for the nine months ended September 30, 2025 increased to $18,711,335 by $7,515,447, or 67.13%, from $11,195,888 for the same period in 2024. This increase was mainly due to the opening of new clinics resulting in the increased demand for medical equipment from new clinics and replacing laser hair removal equipment from existing clinics as well as the appreciation of JPY.

Others

The other revenues for the nine months ended September 30, 2025 decreased to $12,848,127 by $2,751,016, or 17.64%, from $15,599,143 for the same period in 2024. This decrease was mainly due to the disposal of its subsidiaries, Kijimadairakanko Inc. and Skynet Academy Co., Ltd., in December 2024, offset by revenues from Aesthetic Healthcare Holdings Pte. Ltd. and its subsidiaries, which were acquired in November 2024.

Cost of Revenues

Cost of revenues for the nine months ended September 30, 2025 was $35,685,635 compared to $38,816,865 for the same period in 2024. The decrease was mainly due to the Company’s effort of the cost reduction, as well as the discontinuation of clinic operation supporting services provided by Shobikai Sub to MCs since the third quarter of 2024, and the Company then terminated the employment of the related staff. As a result, cost of revenues decreased overall, despite a partial offset from higher purchase costs resulting from the demand for replacing laser hair removal equipment from the MCs.

Gross Profit

Gross profit for the nine months ended September 30, 2025 was $98,355,148 compared to $122,178,140 for the same period in 2024. The decrease in gross profit by $23,822,992 or 19.50% was mainly due to the decrease in franchising revenue and management services revenue with relatively high gross margin as a result of the factors described above.

Operating Expenses

Operating expenses for the nine months ended September 30, 2025 and 2024 were as follows:

For the Nine Months Ended September 30, 2025 2024 Variance Amount%
Salaries and welfare $19,805,407 $21,228,566 $(1,423,159) (6.70)%
Depreciation and amortization expense 1,643,588 1,912,284 (268,696) (14.05)%
Consulting and professional service fees 11,589,322 10,279,107 1,310,215 12.75%
Advertising expense 1,956,774 1,556,483 400,291 25.72%
Taxes and dues 908,051 400,943 507,108 126.48%
Recruiting expense 544,643 1,450,109 (905,466) (62.44)%
Lease expense 1,807,212 1,836,717 (29,505) (1.61)%
Office, utility and other expenses 5,462,645 5,120,428 342,217 6.68%
Stock-based compensation — 12,807,455 (12,807,455) (100.00)%
Total $43,717,642 $56,592,092 $(12,874,450) (22.75)%

The operating expenses decreased to $43,717,642 for the nine months ended September 30, 2025 by $12,874,450, or 22.75%, from $56,592,092 for the same period in 2024. The decrease was mainly due to the decrease in stock-based compensation and salaries and welfare, partially offset by the increase in consulting and professional service fees.

Stock-based compensation was recognized as an expense for the nine months ended September 30, 2024 related to warrants issued to a service provider that supported SBC’s listing process. No such expense was recognized for the nine months ended September 30, 2025.

Salaries and welfare decreased by $1,423,159 or 6.70%, to $19,805,407 for the nine months ended September 30, 2025 from $21,228,566 for the same period in 2024, mainly due to the disposal of a subsidiary, Kijimadairakanko Inc. in December 2024 and the decrease in the compensation to the director and CEO of the Company.

Consulting and professional service fees increased by $1,310,215, or 12.75%, to $11,589,322 for the nine months ended September 30, 2025 from $10,279,107 for the same period in 2024, mainly due to the increase in legal, tax, and market research expenses associated with the Company’s listing.

Other Income (Expenses)

Other income (expenses) for the nine months ended September 30, 2025 and 2024, were as follows:

For the Nine Months Ended September 30, 2025 2024 Variance Amount%
Interest income $198,599 $37,283 $161,316 432.68%
Interest expense (104,493) (15,898) (88,595) 557.27%
Other income 2,711,134 721,894 1,989,240 275.56%
Other expenses (2,836,288) (2,746,450) (89,838) 3.27%
Gain on redemption of life insurance policies 8,746,138 — 8,746,138 100.00%
Change in fair value of cryptocurrencies 146,036 — 146,036 100.00%
Gain on disposal of subsidiary — 3,813,609 (3,813,609) (100.00)%
Total $8,861,126 $1,810,438 $7,050,688 389.45%

Other income (expenses), net was $8,861,126 for the nine months ended September 30, 2025 compared to $1,810,438 for the same period in 2024. The increase in other income (expense) by $7,050,688 or 389.45% was mainly due to a gain on redemption of life insurance policies of $8,746,138 in 2025, offset by the gain on disposal of subsidiary of $3,813,609 recognized in the nine months ended September 30, 2024 while no such event recognized in the same period in 2025. In addition, the other income was $2,711,134 for the nine months ended September 30, 2025, as compared to $721,894 for the nine months ended September 30, 2024, mainly due to an unrealized gain recognized on investment in a public entity with a readily determinable fair value - related party. The other expense was $2,836,288 for the nine months ended September 30, 2025, as compared to $2,746,450 for the nine months ended September 30, 2024. Change in fair value of cryptocurrencies was $146,036 for the nine months ended September 30, 2025, as compared to nil for the nine months ended September 30, 2024, due to the Company purchased cryptocurrencies in the nine months ended September 30, 2025, which resulted in the fair value change of the cryptocurrencies during the current period.

Income Tax Expense

Income tax expense for the nine months ended September 30, 2025 was $26,733,504 compared to $27,254,478 for the same period in 2024. The decrease in income tax expense by $520,974 or 1.91% was mainly due to the increase of deferred tax expenses recognized and the appreciation of JPY.

The effective tax rate was 42.10% and 40.44% for the nine months ended September 30, 2025 and 2024, respectively.

Net Income

As a result of the foregoing, we reported a net income of $36,765,128 for the nine months ended September 30, 2025, representing a decrease of $3,376,880 or 8.41% from $40,142,008 for the nine months ended September 30, 2024.

Net Income (Loss) Attributable to Non-controlling Interests

Net loss attributable to non-controlling interests was $20,194 for the nine months ended September 30, 2025, as compared to net income attributable to non-controlling interests of $66,954 for the nine months ended September 30, 2024.

Liquidity and Capital Resources

As of September 30, 2025, the Company had $127,431,318 in cash and cash equivalents compared to $125,044,092 as of December 31, 2024. In addition, the Company had $61,194,381 in accounts receivable as of September 30, 2025 compared to $30,260,113 as of December 31, 2024. The Company’s accounts receivable includes balances due from customers for the services and goods provided by the Company and accepted by customers.

As of September 30, 2025, the Company’s working capital balance was $182,618,388. In assessing liquidity, management monitors and analyzes the Company’s cash and cash equivalents, ability to generate sufficient future earnings, and operating and capital investment commitments. The Company believes that its current cash and cash equivalents from operations and borrowings from banks will be sufficient to meet its working capital needs for the next 12 months from the date of issuance of the unaudited financial statements included in this Quarterly Report.

To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, equity financings or a combination of these potential sources of funds. While we face uncertainties regarding the size and timing of our fundraising, which will be affected by general economic, financial, and other factors that may be beyond our control, we believe that we will be able to continue to meet our current business needs through the use of cash flows generated from operations and stockholder working capital, as needed.

The Company evaluates its capital allocation practices with the objective of enhancing shareholder value, while considering performance, the business environment, macroeconomic conditions and other relevant factors. The Company expects to deploy capital for investment opportunities that align with its growth strategy, selectively pursuing prospects in the expanding global medical aesthetics market. Additionally, the Company continues to evaluate alternative methods for deployment of capital, including in the form of dividends to stockholders and repurchases of shares of common stock. The actual timing, manner and value of any such options will depend on several factors, including the market price of our stock, general market and economic conditions, our liquidity requirements, applicable legal requirement and other business considerations.

Cash Flows for the nine months ended September 30, 2025 and 2024

The following table provides a summary of our cash flows for the periods indicated.

For the Nine Months Ended September 30, 2025 2024 Variance Amount%
Net cash provided by (used in) operating activities $(27,295,426) $27,886,231 $(55,181,657) (197.88)%
Net cash provided by (used in) investing activities 3,239,523 (5,554,039) 8,793,562 (158.33)%
Net cash provided by financing activities 18,470,001 11,584,038 6,885,963 59.44%
Effect of exchange rate changes 7,973,128 453,908 7,519,220 1,656.55%
Net change in cash and cash equivalents 2,387,226 34,370,138 (31,982,912) (93.05)%
Cash and cash equivalents as of the beginning of the period 125,044,092 103,022,932 22,021,160 21.38%
Cash and cash equivalents as of the end of the period $127,431,318 $137,393,070 $(9,961,752) (7.25)%

Operating Activities

Net cash used in operating activities was $27,295,426 for the nine months ended September 30, 2025, mainly derived from net income of $36,765,128 for the period, reconciled by a gain on redemption of life insurance policies of $8,746,138 and deferred income tax expense of $9,104,235, and net changes in operating assets and liabilities, which mainly included an increase in accounts receivable - related parties of $28,031,690, an increase in finance lease receivables – related parties of $9,227,612, a decrease in customer loans receivable of $12,153,263, a decrease in notes and other payables - related parties of $12,759,536, a decrease in advances from customers – related parties of $5,470,844, and a decrease in income tax payable of $19,936,155.

Net cash provided by operating activities was $27,886,231 for the nine months ended September 30, 2024, mainly derived from net income of $40,142,008 for the period, reconciled by stock-based compensation of $12,807,455, a gain on disposal of subsidiary of $3,813,609, and net changes in operating assets and liabilities, which mainly included a decrease in customer loans receivable of $12,860,220, a decrease in accounts payable of $10,511,619, a decrease in notes and other payables – related parties of $14,030,092, and a decrease in accrued liabilities and other current liabilities of $9,010,270.

Investing Activities

During the nine months ended September 30, 2025, net cash provided by investing activities of $3,239,523 was mainly the result of proceeds from redemption of life insurance policies of $17.7 million, offset by the cash paid for acquisition of subsidiary, net of cash acquired of $14.9 million.

During the nine months ended September 30, 2024, net cash used in investing activities of $5,554,039 was mainly the result of payments made on behalf of a related parties of $5.2 million, purchase of convertible note of $1.7 million, purchase of property and equipment of $2.0 million, and disposal of subsidiary, net of cash disposed of $0.8 million, offset by the repayments from related parties of $6.0 million.

Financing Activities

During the nine months ended September 30, 2025, net cash provided by financing activities of $18,470,001 was mainly due to the borrowings from long-term loans of $14.9 million and the deemed contribution in connection with the price modification on disposal of property and equipment of $9.7 million, offset by repurchase of common stock of $5.0 million.

During the nine months ended September 30, 2024, net cash provided by financing activities of $11,584,038 was mainly due to the proceeds from reverse recapitalization, net of transaction costs of $11.7 million.

Recent Developments

Acquisition of Waqoo, Inc. (Tender Offer and Privately Negotiated Purchases)

On November 13, 2025, the Board of Directors of the Company approved the commencement of a tender offer (the “Tender Offer”) for shares of the common stock of Waqoo, Inc. (“Waqoo”), a Japanese corporation listed on the Tokyo Stock Exchange Growth Market.

As of the date of this report, the Company owns 353,600 shares of Waqoo, representing approximately 9.49% of Waqoo’s outstanding shares. In addition, the Company’s Chief Executive Officer, Dr. Yoshiyuki Aikawa, personally holds 989,802 shares of Waqoo, representing approximately 26.58% of Waqoo’s outstanding shares.

The following transactions have been structured:

  • Tender Offer: The Company will conduct the Tender Offer for up to 575,000 shares of Waqoo’s common stock, at a price per share to be determined, from November 14, 2025 through December 12, 2025 (20 business days). Settlement of the Tender Offer is expected to take place on December 19, 2025. The tender offer agent will be SBI Securities Co., Ltd.; and
  • Off-Market Transfer: Subject to the settlement of the Tender Offer, the Company will acquire from Dr. Aikawa all 989,802 shares of Waqoo held by him pursuant to a share transfer agreement dated November 13, 2025.

Following completion of the Tender Offer and the off-market transfer, the Company intends to make Waqoo its consolidated subsidiary and Waqoo will become part of the Company’s consolidated group.

Through this transaction, the Company aims to further accelerate Waqoo’s research and development initiatives and to integrate its advanced technologies and expertise within the SBC Group. By leveraging Waqoo’s capabilities, the Group intends to enhance its offerings in clinical areas such as AGA and orthopedics, develop new treatment methods and proprietary services, and strengthen overall competitiveness.

In addition, the Company and Waqoo will jointly promote the development and implementation of skincare products informed by clinical insights, establishing a seamless framework from research to commercialization. Waqoo’s processing and research know-how is also expected to serve as a technological foundation for the Company’s international operations, supporting joint efforts toward the practical realization of regenerative medicine.

Contractual Obligations

Lease Agreements

The Company holds a significant number of leases classified as operating leases for offices and sublease purposes, and finance leases for certain medical equipment.

As of September 30, 2025, the future maturity of lease liabilities is as follows:

Years ending December 31, Finance Lease Operating Lease
Remaining of 2025 $41,361 $1,177,273
2026 132,469 2,661,733
2027 76,237 893,682
2028 43,213 235,745
2029 7,004 128,596
Thereafter — 58,186
Total undiscounted lease payments 300,284 5,155,215
Less: imputed interest (16,004) (45,178)
Total lease liabilities $284,280 $5,110,037

Bank and Other Borrowings

The Company borrowed loans from various banks and a financial institution for working capital purpose.

As of September 30, 2025, future minimum borrowing payments are as follows:

Years ending December 31, Principal Repayment
Remaining of 2025 $757,633
2026 3,041,796
2027 9,788,975
2028 2,974,209
2029 2,974,209
Thereafter 1,585,972
Total $21,122,794

Off-Balance Sheet Arrangements (Off-Balance Sheet Transactions)

There are no off-balance sheet arrangements as of September 30, 2025 and December 31, 2024.

Foreign Exchange Rate Risk

We are exposed to foreign currency exchange rate fluctuations because our business is primarily conducted in Japan and most of our revenues and costs are denominated in Japanese yen, whereas our reporting currency is U.S. dollar. The weakening of the Japanese yen against the U.S. dollar would have a negative impact on our financial results and vice versa.

Critical Accounting Policies and Estimates

We prepare our consolidated financial statements in conformity with U.S. GAAP, which requires us to make judgments, estimates and assumptions. We continually evaluate these estimates and assumptions based on the most recently available information, our own historical experiences and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from our expectations as a result of changes in our estimates.

We believe that there have been no material changes to our critical accounting policies and estimates from those disclosed in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates” of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025.

Emerging Growth Company

We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and we will take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.

Smaller Reporting Company

Additionally, we are a “smaller reporting company,” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the last business day of our second fiscal quarter, or (ii) our annual revenue exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the last business day of our second fiscal quarter. If we continue to be a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from these certain reduced disclosure requirements that are available to smaller reporting companies.

Market risk

As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Controls and procedures

As filed, 3,315 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report. Based on this evaluation, management concluded that our disclosure controls and procedures were not effective as of September 30, 2025 to provide reasonable assurance that information required to be disclosed in reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure due to identification of material weaknesses.

Despite the identified material weaknesses, we believe that our unaudited consolidated financial statements and other information contained in this Quarterly Report fairly present, in all material respects, our financial condition, and results of operations for the periods presented.

We remain committed to ongoing improvements in our disclosure controls and internal control over financial reporting, including execution of the remediation plan disclosed under “Part II, Item 9A. Controls and Procedures” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025. The material weaknesses previously identified in the Annual Report remained un-remediated as of September 30, 2025.

Inherent Limitation on the Effectiveness of Internal Control

The effectiveness of any system of internal control over financial reporting is subject to inherent limitations. These include the exercise of judgment in designing, implementing, and operating controls, as well as the inherent inability to completely eliminate the risk of misconduct or error. Accordingly, while we aim to establish robust controls, any system, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Additionally, the design of our disclosure controls and procedures is impacted by resource constraints and the necessity for management to balance the benefits of potential controls against their associated costs. Moreover, projections of effectiveness into future periods are subject to risks that controls may become inadequate over time due to evolving conditions or diminished compliance. We will continue to monitor and enhance our internal control as necessary or appropriate, but we cannot provide assurance that these improvements will fully eliminate all risks of material misstatement.

Changes in Internal Control over Financial Reporting

Other than the remediation efforts described above, there have been no material changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) during the three months ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 905 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Investing in our securities involves a high degree of risk. These risks are more fully described under “Part I, Item 1A. Risk Factors” of the Annual Report in addition to the information in this Quarterly Report. There have been no material changes to the risk factors set forth in the Annual Report. Any of these factors could result in a material adverse effect on our results of operations or financial condition.

Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. If any such risks materialize, it could have a material adverse effect on our business, financial condition, results of operations, and growth prospects and cause the trading price of our securities to decline. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-07-01 to 2025-09-30$43.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2025-01-01 to 2025-09-30$134.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2025-07-01 to 2025-09-30$12.7mus-gaap:CostOfRevenue
Cost of revenue9 months2025-01-01 to 2025-09-30$35.7mus-gaap:CostOfRevenue
Gross profit3 months2025-07-01 to 2025-09-30$30.6mus-gaap:GrossProfit
Gross profit9 months2025-01-01 to 2025-09-30$98.4mus-gaap:GrossProfit
Selling, general and administrative3 months2025-07-01 to 2025-09-30$14.7mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2025-01-01 to 2025-09-30$43.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-07-01 to 2025-09-30$15.9mus-gaap:OperatingIncomeLoss
Operating income9 months2025-01-01 to 2025-09-30$54.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-07-01 to 2025-09-30$44.9kus-gaap:InterestExpense
Interest expense9 months2025-01-01 to 2025-09-30$95.5kus-gaap:InterestExpense
Income tax3 months2025-07-01 to 2025-09-30$5.7mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2025-01-01 to 2025-09-30$26.7mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-07-01 to 2025-09-30$12.8mus-gaap:NetIncomeLoss
Net income9 months2025-01-01 to 2025-09-30$36.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-07-01 to 2025-09-30$0.12us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2025-01-01 to 2025-09-30$0.36us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-07-01 to 2025-09-30$0.12us-gaap:EarningsPerShareBasic
Basic EPS9 months2025-01-01 to 2025-09-30$0.36us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-07-01 to 2025-09-30102,642,634 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2025-01-01 to 2025-09-30103,139,851 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2025-01-01 to 2025-09-30−$27.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2025-01-01 to 2025-09-30$603.5kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2025-01-01 to 2025-09-30$5.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2025-09-30$127.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-09-30$227.2mus-gaap:AssetsCurrent
Total assetsAt period end2025-09-30$321.4mus-gaap:Assets
Current liabilitiesAt period end2025-09-30$44.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-09-30$73.3mus-gaap:Liabilities
Long-term debtAt period end2025-09-30$21.1mus-gaap:LongTermDebt
Current portion of debtAt period end2025-09-30$250.5kus-gaap:DebtCurrent
Shareholders' equityAt period end2025-09-30$248.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-25-281466. Last ingested by Listed: Nov 14, 2026, 11:07 ET. Listed shows no prices and gives no investment advice.